Genome editing for p63 in a head-and-neck squamous carcinoma cell line
Project/Area Number |
15K11090
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pathobiological dentistry/Dental radiology
|
Research Institution | Kanagawa Dental College |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
HATA Ryu-Ichiro 神奈川歯科大学, 歯学部, 特任教授 (10014276)
KATOH Iyoko 山梨大学, 総合研究部, 准教授 (20333297)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | p63 / CRISPR-Cas9 / ゲノム編集 |
Outline of Final Research Achievements |
P63(TP63), one of the tumor suppressor p53 gene family, is highly expressed in non-invasive squamous carcinomas of head-and-neck. To investigate the role of p63, we attempted genome editing with CRISPR-Cas9. P63 has TA and ΔN type transcription start sites, of which we focused on the first exon of TA-p63. We selected drug-resistant cells after transfection of carcinoma cells with a guide vector containing the gRNA and Cas9 together with a donor vector containing a drug-resistance gene between the 5’ and 3’ flanking regions of the target site. This procedure allowed recombination at the expected site, but only at a single allele. To achieve the biallelic knockout, we needed to perform step-wise transfection-and-selection cycles using two donor vectors with different drug resistance genes.
|
Report
(4 results)
Research Products
(20 results)
-
[Journal Article] TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells2017
Author(s)
Toyonobu Maeda, Atsuko Suzuki, Kaori Koga, Chihiro Miyamoto, Yojiro Maehata, Shigeyuki Ozawa, Ryu-Ichiro Hata, Yoji Nagashima, Kazuki Nabeshima, Kaoru Miyazaki, Yasumasa Kato
-
Journal Title
Oncotarget
Volume: 8
Issue: 45
Pages: 78312-78326
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.2016
Author(s)
Kondo T, Ozawa S, Ikoma T1, Yang XY, Kanamori K, Suzuki K, Iwabuchi H, Maehata Y, Miyamoto C, Taguchi T, Kiyono T, Kubota E, Hata RI
-
Journal Title
Oncogenesis
Volume: 5
Issue: 7
Pages: 1-10
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Chemokine CXCL14 is a multistep tumor suppressor.2016
Author(s)
Xiao-Yan Yang, Chihiro Miyamoto, Tetsu Akasaka, Kazuhito Izukuri, Yojiro Maehata, Takeharu Ikoma, Shigeyuki Ozawa, Ryu-Ichiro Hata
-
Journal Title
Journal of Oral Biosciences
Volume: 58
Issue: 1
Pages: 16-22
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Chemokine CXCL14 is a multistep tumor suppressor.2015
Author(s)
Ryu-Ichiro Hata, Kazuhito Izukuri, Yasumasa Kato, Soichiro Sasaki, Chihiro Miyamoto, Tetsu Akasaka, Xiaoyan Yang, Yojiro Maehata, Yoji Nagashima, Kazuyoshi Takeda, Tohru Kiyono, Naofumi Mukaida, Masaru Taniguchi
Organizer
2015 American Association of Cancer Research Annual Meeting
Place of Presentation
Philadelphia
Year and Date
2015-04-18
Related Report
-
-